5.51
price down icon10.41%   -0.64
pre-market  プレマーケット:  5.71   0.20   +3.63%
loading
前日終値:
$6.15
開ける:
$6.11
24時間の取引高:
1.10M
Relative Volume:
1.05
時価総額:
$298.55M
収益:
$1.02B
当期純損益:
$-757.20M
株価収益率:
-0.3733
EPS:
-14.76
ネットキャッシュフロー:
$-257.90M
1週間 パフォーマンス:
-5.65%
1か月 パフォーマンス:
-42.00%
6か月 パフォーマンス:
-29.99%
1年 パフォーマンス:
+145.98%
1日の値動き範囲:
Value
$5.50
$6.23
1週間の範囲:
Value
$5.26
$6.36
52週間の値動き範囲:
Value
$1.8201
$15.10

Emergent Biosolutions Inc Stock (EBS) Company Profile

Name
名前
Emergent Biosolutions Inc
Name
セクター
Healthcare (1169)
Name
電話
240-631-3200
Name
住所
300 PROFESSIONAL DR, GAITHERSBURG, MD
Name
職員
1,600
Name
次回の収益日
2025-03-03
Name
最新のSEC提出書
Name
EBS's Discussions on Twitter

EBS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
EBS
Emergent Biosolutions Inc
5.51 298.55M 1.02B -757.20M -257.90M -14.76
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
160.06 71.67B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.03 47.44B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.19 46.08B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.46 18.86B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
ITCI
Intra Cellular Therapies Inc
131.36 13.97B 612.78M -86.37M -62.91M -0.87

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-30 開始されました H.C. Wainwright Buy
2024-08-22 開始されました Rodman & Renshaw Buy
2024-03-07 アップグレード The Benchmark Company Hold → Buy
2023-11-20 再開されました JP Morgan Underweight
2023-08-29 ダウングレード The Benchmark Company Buy → Hold
2023-04-10 アップグレード The Benchmark Company Hold → Buy
2023-03-17 ダウングレード JP Morgan Neutral → Underweight
2022-11-10 ダウングレード The Benchmark Company Buy → Hold
2022-04-29 ダウングレード Cantor Fitzgerald Overweight → Neutral
2022-01-20 アップグレード The Benchmark Company Hold → Buy
2021-11-08 ダウングレード The Benchmark Company Buy → Hold
2021-05-05 ダウングレード Argus Buy → Hold
2021-04-07 開始されました The Benchmark Company Buy
2021-02-24 アップグレード Chardan Capital Markets Neutral → Buy
2021-02-19 ダウングレード Chardan Capital Markets Buy → Neutral
2021-01-08 ダウングレード Wells Fargo Overweight → Equal Weight
2020-09-14 再開されました JP Morgan Neutral
2020-07-31 繰り返されました Chardan Capital Markets Buy
2019-09-12 開始されました Guggenheim Buy
2019-09-04 アップグレード Wells Fargo Market Perform → Outperform
2018-11-02 アップグレード Goldman Neutral → Buy
2018-08-03 繰り返されました Chardan Capital Markets Buy
2018-06-13 開始されました Argus Buy
2018-04-25 ダウングレード Wells Fargo Outperform → Market Perform
2018-01-24 開始されました Goldman Neutral
2018-01-16 繰り返されました Chardan Capital Markets Buy
2016-06-28 繰り返されました Singular Research Buy
2016-04-15 開始されました Chardan Capital Markets Buy
2016-03-28 開始されました Singular Research Buy
2016-02-19 開始されました Wells Fargo Outperform
2014-05-15 開始されました Summer Street Research Buy
2011-05-31 繰り返されました WBB Securities Strong Buy
2011-01-10 繰り返されました Wedbush Outperform
2010-11-05 繰り返されました Wedbush Outperform
2010-08-18 アップグレード WBB Securities Buy → Strong Buy
2010-08-06 繰り返されました Caris & Company Buy
すべてを表示

Emergent Biosolutions Inc (EBS) 最新ニュース

pulisher
Mar 13, 2025

Emergent signs financial investment agreement with Swiss Rockets - Yahoo Finance

Mar 13, 2025
pulisher
Mar 13, 2025

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by ... - The Bakersfield Californian

Mar 13, 2025
pulisher
Mar 13, 2025

First OTC Narcan Program Targets High-Risk Construction Workers to Combat Overdose Crisis - StockTitan

Mar 13, 2025
pulisher
Mar 13, 2025

Emergent BioSolutions to invest in Rocketvax for vaccine developments - MSN

Mar 13, 2025
pulisher
Mar 12, 2025

Emergent BioSolutions to sell Baltimore-Bayview manufacturing site for $36.5M - MSN

Mar 12, 2025
pulisher
Mar 12, 2025

Emergent BioSolutions director Fowler sells $204,050 in stock - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Emergent BioSolutions director Zoon sells $57,300 in stock - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Emergent BioSolutions director Fowler sells $204,050 in stock By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 12, 2025

Emergent Bio and Rocketvax in investment deal and partnership - The Pharma Letter

Mar 12, 2025
pulisher
Mar 12, 2025

Emergent BioSolutions and Rocketvax Announce Investment Agreement - Contract Pharma

Mar 12, 2025
pulisher
Mar 12, 2025

Emergent Biosolutions And Rocketvax Announce Investment Agreement And Pursuit Of A Strategic Relationship For Next-Generation Product Candidates - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

Emergent BioSolutions to Invest in Swiss Rockets, Rocketvax -March 12, 2025 at 08:40 am EDT - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

Emergent BioSolutions, Rocketvax announce investment agreement - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Emergent BioSolutions and Rocketvax Ltd Announce Strategic Investment and Partnership to Advance Next-Generation Vaccine Development - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Emergent BioSolutions and Rocketvax Announce Investment - GlobeNewswire

Mar 12, 2025
pulisher
Mar 12, 2025

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates - GlobeNewswire Inc.

Mar 12, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Trims Stock Position in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Syngene buys its first manufacturing facility in US for USD36.5 million - Medical Dialogues

Mar 11, 2025
pulisher
Mar 10, 2025

Emergent BioSolutions Sells Baltimore Facility to Syngene - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Gaithersburg's Emergent BioSolutions to sell Baltimore plant for $36.5M - The Business Journals

Mar 10, 2025
pulisher
Mar 10, 2025

Drug manufacturer to sell Baltimore plant for $36.5M - The Business Journals

Mar 10, 2025
pulisher
Mar 10, 2025

Emergent BioSolutions sells Baltimore facility to Syngene By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Emergent BioSolutions drops after Syngene buys co's unit for $36.5 mln - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

India's Syngene International acquires first US biologics facility for $36.5 million - Yahoo Finance

Mar 10, 2025
pulisher
Mar 10, 2025

Emergent to Sell Baltimore-Bayview Facility for $36.5 Million -March 10, 2025 at 10:28 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Emergent BioSolutions sells Baltimore facility to Syngene - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International - The Manila Times

Mar 10, 2025
pulisher
Mar 10, 2025

Emergent BioSolutions to sell Baltimore-Bayview facility for $36.5M - TipRanks

Mar 10, 2025
pulisher
Mar 07, 2025

Emergent BioSolutions’ (EBS) Buy Rating Reiterated at HC Wainwright - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Q1 Earnings Estimate for EBS Issued By HC Wainwright - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Emergent BioSolutions Inc. (NYSE:EBS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance

Mar 06, 2025
pulisher
Mar 05, 2025

Is Emergent BioSolutions (NYSE:EBS) Weighed On By Its Debt Load? - Simply Wall St

Mar 05, 2025
pulisher
Mar 04, 2025

Emergent BioSolutions’ Earnings Call: Balancing Achievements and Challenges - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Emergent BioSolutions Reports Strong 2024 Financial Turnaround - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

Where Emergent BioSolutions Stands With Analysts - Benzinga

Mar 04, 2025
pulisher
Mar 04, 2025

Emergent BioSolutions Inc. (NYSE:EBS) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 04, 2025
pulisher
Mar 04, 2025

H.C. Wainwright maintains Buy rating on Emergent BioSolutions stock By Investing.com - Investing.com UK

Mar 04, 2025
pulisher
Mar 04, 2025

Emergent Bio's Q4 Revenue Plunges Nearly 30%, Forecasts 18% To 28% Drop For 2025 - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

Emergent BioSolutions Inc. SEC 10-K Report - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

(EBS) Trading Signals - Stock Traders Daily

Mar 04, 2025
pulisher
Mar 04, 2025

Emergent BioSolutions Inc (EBS) Q4 2024 Earnings Call Highlights: Strategic Advancements Amid ... By GuruFocus - Investing.com Canada

Mar 04, 2025
pulisher
Mar 04, 2025

Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

Emergent Biosolutions: Q4 Earnings Snapshot - Midland Daily News

Mar 04, 2025
pulisher
Mar 04, 2025

Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript - AOL

Mar 04, 2025
pulisher
Mar 04, 2025

Emergent BioSolutions Inc Q4 2024 Earnings: EPS of -$0.58 Misses Estimate, Revenue Falls Short at $194.7 Million - GuruFocus.com

Mar 04, 2025
pulisher
Mar 04, 2025

Emergent BioSolutions Inc (EBS) Q4 2024 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance

Mar 04, 2025
pulisher
Mar 03, 2025

Emergent BioSolutions Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

EMERGENT BIOSOLUTIONS Earnings Results: $EBS Reports Quarterly Earnings - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Emergent BioSolutions Swings to Q4 Earnings, Revenue Declines -- Shares Fall After Hours - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

Emergent BioSolutions tumbles 8% as Q4 revenue, 2025 guidance disappoints - Seeking Alpha

Mar 03, 2025

Emergent Biosolutions Inc (EBS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$10.31
price down icon 0.77%
$33.62
price up icon 0.63%
$99.29
price down icon 1.55%
$8.98
price down icon 2.81%
$108.99
price down icon 0.07%
$131.36
price up icon 0.08%
大文字化:     |  ボリューム (24 時間):